

#2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: KNICK et al.

International Application No. PCT/EP99/05271

International Filing Date: July 23, 1999

For: *COMBINATION OF AN ANTI-EP-CAM
ANTIBODY WITH A CHEMOTHERAPEUTIC
AGENT***BOX PCT/DO/EO/US**
Commissioner for Patents
Washington, D.C. 20231**INFORMATION DISCLOSURE STATEMENT**

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97


- ☐ Copies of the references are enclosed
- ☐ Copies of the references were submitted in parent application Serial No. _____. (37 CFR 1.98(d))
- ☒ A copy of the International Search Report which issued on International Application No. PCT/EP99/05271 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,
- whichever occurs first.
- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Virginia C. Bennett
Attorney of Record
Registration No. 37,092

Date: January 18, 2002

GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-3934
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO. PF3513USW	SERIAL NO. To be assigned
	APPLICANT KNICK et al.	
	FILING DATE Concurrently herewith	GROUP

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page ____

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
1.	EP 0252741 A	01/13/1988	EPO			

Continue on page ____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

2.	Bleiberg, "Continuing the fight against advanced colorectal cancer: new and future treatment options," <i>Anti-Cancer Drugs</i> 9:1 18-28 (January 1998).
3.	Bokemeyer et al., "Current aspects of adjuvant and palliative chemotherapy in colorectal carcinoma! Aktuelle Aspekte zur adjuvanten und palliativen Chemotherapie beim kolorektalen Karzinom," <i>Schweizerische Rundschau Fur Medizin Praxis</i> 86:39 1510-1516 (September 1997).
4.	Casillas et al., "Adjuvant therapy for colorectal cancer: present and future perspectives," <i>Diseases of the Colon and Rectum</i> 40:8 977-992 (August 1997).
5.	Elias et al., "Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma," <i>American Journal of Respiratory and Critical Care Medicine</i> 15:4 1114-1122 (October 1994).
6.	Haisma et al., "A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer," <i>British Journal of Cancer</i> 66:3 474-478 (September 1992).
7.	Kievit et al., "Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer," <i>International Journal of Cancer</i> 71:2 237-245 (April 1997).
8.	Paul et al., "Treatment of advanced measurable or evaluable pancreatic carcinoma with 17-1A murine monoclonal antibody alone or in combination with 5-fluorouracil, adriamycin and mitomycin (FAM)," <i>Hybridoma</i> 5 Suppl:1 S171-S174 (July 1986).
9.	Schwartzberg, "Chemotherapy plus PANOREX (17-1A monoclonal antibody) as adjuvant therapy for colon cancer: Ongoing studies," <i>Cancer Investigation</i> 17Suppl:1 32-34 (1999)

Continue on page ____

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.